OpenNashEarnings

Daiichi Sankyo (4568) · Pharmaceuticals

Daiichi Sankyo Q1 FY2026 earnings: summary, key numbers & outlook

Results filed 31 Jul 2026 · Quarter ended 30 Jun 2026

Slides (38 pages)Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Enhertu won two early-breast-cancer approvals in the US and Datroway added first-line triple-negative breast cancer, widening the DXd antibody drug conjugate franchise.

Daiichi Sankyo's growth came from its two main cancer drugs, Enhertu and Datroway. In May the US approved Enhertu before and after surgery for HER2 positive early breast cancer, and Datroway as first-line treatment for triple-negative breast cancer. Europe approved Enhertu for HER2 positive solid tumors in June. Datroway has now treated approx. 7,000 patients globally, about 1.4 times the prior quarter.

Management is concentrating resources on five DXd antibody drug conjugates (ADCs) and aims to find new core technologies by fiscal 2030. Next milestones include a US decision on ifinatamab deruxtecan in small cell lung cancer (PDUFA date Oct 10, 2026) and several late-stage Datroway readouts. The tension is that profit-sharing with AstraZeneca rises with Enhertu sales, and the company is restructuring its EU specialty business.

Slides & documents

Open the slide deck (PDF, 38 pages) ↗

Daiichi Sankyo Q1 FY2026 slide deck, page 1Daiichi Sankyo Q1 FY2026 slide deck, page 2Daiichi Sankyo Q1 FY2026 slide deck, page 3Daiichi Sankyo Q1 FY2026 slide deck, page 4Daiichi Sankyo Q1 FY2026 slide deck, page 5Daiichi Sankyo Q1 FY2026 slide deck, page 6

Showing the first 6 of 38 pages.

Results documents

Key numbers

Revenue · GAAP
JPY574.7 billion

up 21.1% year on year

Operating profit · GAAP
JPY85.1 billion

down 12.0% year on year

Profit attributable to owners of the Company · GAAP
JPY68.6 billion

down 19.7% year on year

Diluted EPS (JPY) · GAAP
37.70

from 46.01 a year ago

Core operating profit · non-GAAP
JPY107.3 billion

up 6.2% year on year

Free cash flow (JPY billions)
48.8B

from -37.4 a year ago

Segment or metricValueChange
Oncology Business UnitJPY197.4 billionup 50.5% year on year
Japan Business UnitJPY120.0 billiondown 3.9% year on year
EU Specialty Business UnitJPY74.7 billionup 17.1% year on year
ASCA Business UnitJPY68.7 billionup 21.0% year on year
American Regent UnitJPY42.2 billiondown 14.3% year on year
Daiichi Sankyo Healthcare UnitJPY22.6 billionup 7.9% year on year
Where each number comes from
  • Revenue: “Revenue in the first three months of the year ending March 31, 2027 increased by JPY100.1 billion, or 21.1% year on year, to JPY574.7 billion.”
  • Operating profit: “Operating profit decreased by JPY11.6 billion, or 12.0% year on year, to JPY85.1 billion.”
  • Profit attributable to owners of the Company: “Profit attributable to owners of the Company decreased by JPY16.9 billion, or 19.7% year on year, to JPY68.6 billion.”
  • Diluted EPS (JPY): “Basic earnings per share (JPY) 46.03 37.72 Diluted earnings per share (JPY) 46.01 37.70 Condensed Interim Consolidated Statement of Comprehensive Income”
  • Core operating profit: “Core operating profit increased by JPY6.3 billion, or 6.2% year on year, to JPY107.3 billion.”
  • Free cash flow (JPY billions): “Free cash flows (Cash flows from operating activities and investing activities) -37.4 48.8 86.1”
  • Oncology Business Unit: “Revenue from the Unit increased by JPY66.2 billion, or 50.5% year on year, to JPY197.4 billion and the revenue in local currency”
  • Japan Business Unit: “Revenue from the Unit decreased by JPY4.9 billion, or 3.9% year on year, to JPY120.0 billion due to decreases in sales of Lixiana”
  • EU Specialty Business Unit: “Revenue from the Unit increased by JPY10.9 billion, or 17.1% year on year, to JPY74.7 billion and the revenue in local currency”
  • ASCA Business Unit: “Revenue from the Unit increased by JPY11.9 billion, or 21.0% year on year, to JPY68.7 billion due to the growth in sales of Enhertu”
  • American Regent Unit: “Revenue from American Regent Unit decreased by JPY7.1 billion, or 14.3% year on year, to JPY42.2 billion and the revenue in local currency”
  • Daiichi Sankyo Healthcare Unit: “Revenue from Daiichi Sankyo Healthcare Unit increased by JPY1.6 billion, or 7.9% year on year, to JPY22.6 billion as a result of the increase”

Copied from the press release ↗ and other documents in the company's results page ↗. A figure is published only if its sentence is in those documents.

Outlook

MetricPeriodOutlook
Revenuefiscal year ending March 31, 2027JPY2,340.0 billion
Operating profitfiscal year ending March 31, 2027JPY320.0 billion
Capital expenditure (JPY billions)FY2026200.0

Key takeaways

  1. Enhertu now covers early-stage through metastatic breast cancer

    Two US approvals in May 2026, neoadjuvant and adjuvant, let Enhertu be used from early-stage to metastatic disease. Enhertu sales growth is also led by HER2 positive solid tumors in the US, and Europe approved that tumor-agnostic indication in June.

  2. Datroway adds first-line triple-negative breast cancer

    US approval came in May 2026 for patients not eligible for PD-1/PD-L1 therapy, with new patient starts rising since. Together Enhertu and Datroway can now treat over 90% of metastatic breast cancer patients, based on molecular subtypes.

  3. Datroway uptake is accelerating

    Approx. 7,000 patients have been treated globally, about 1.4 times the prior quarter. US sales are mainly driven by lung cancer, and the company maintained the No. 1 patient share in 3L+ EGFR-mutated NSCLC.

  4. Pipeline decisions cluster around the next two quarters

    The US review of ifinatamab deruxtecan in extensive-stage small cell lung cancer has a PDUFA date of Oct 10, 2026. Several Phase 3 Datroway readouts and an EU decision on Enhertu with pertuzumab are also expected.

  5. Alliances and restructuring shape the profit picture

    Higher profit-sharing with AstraZeneca on Enhertu weighs on selling costs, and the EU Specialty Business Unit is being reorganized. The company also agreed to sell its healthcare unit to Suntory in stages, with 30% transferred on July 1, 2026.

Questions

What new approvals did Enhertu receive this quarter?

In May 2026 the US approved Enhertu for neoadjuvant and adjuvant treatment of HER2 positive early breast cancer. In June 2026 Europe approved it for unresectable or metastatic HER2 positive (IHC3+) solid tumors.

How is Datroway being adopted?

Datroway has treated approx. 7,000 patients globally, about 1.4 times the prior quarter. US sales are mainly driven by lung cancer, and triple-negative breast cancer is growing steadily after its May 2026 US approval.

What is the next major regulatory event for the pipeline?

The US decision on ifinatamab deruxtecan for extensive-stage small cell lung cancer, which has priority review and a PDUFA date of Oct 10, 2026. An EU decision on Datroway in triple-negative breast cancer is also expected in the first half of FY2026.

Where is management steering R&D?

It is concentrating resources on five DXd ADCs and aims to identify next Breakthrough Generating Technologies by fiscal 2030. New programs include DS1025 (a Treg-directed ADC) and a planned Datroway plus rilvegostomig Phase 3 in muscle-invasive urothelial carcinoma.

What are the main business risks in the plan?

Profit sharing with AstraZeneca grows as Enhertu sales rise, offsetting part of the revenue gain in core operating profit guidance. American Regent revenue fell 14.3% on lower Venofer and Injectafer sales, and the EU Specialty unit is being restructured.